Its good and it fills a gap nicely in the schedule and we are now in-clinic, and around the corner from Phase 2 trials with this new addition.
When Cantrixil enters in the next month or so we have two drugs in trials one in phase 1 and one about to go to phase 2.... and with IND + one starting late next year.
They have molecule for phase 2 trials and after phase two we enter into partnership on phase three trials with a big brother it seems a good decision - we could be in funded phase 3 with 'something' within two years.
It also opens the doors for Cantrixil looking for a partner for phase three which must still be a good two years of.
It shortens the time to potential revenue.
If so it proves Novogen can now handle a relationship and the progression to revenue streams - meaning self funded... its a new Novogen.
I like it though haven't read through properly.
![]()
- Forums
- ASX - By Stock
- Ann: In-licencing of Phase II-ready molecule - presentation-NRT.AX
Its good and it fills a gap nicely in the schedule and we are...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online